Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future.
复制标题
DOI：
10.3233/jpd-212976
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Chen SD
中科院分区：
文献类型：
--
作者：
Tan YY;Jenner P;Chen SD
单胺氧化酶-B (MAO-B) 抑制剂通常用于帕金森病 (PD) 的对症治疗。 MAO-B抑制剂单药治疗已被证明对于早期PD的治疗有效且安全，而MAO-B抑制剂作为辅助药物已广泛应用于治疗晚期疾病。 MAO-B抑制剂可以有效改善患者的运动和非运动症状，减少“OFF”时间，并可能预防/延缓疾病进展。在这篇综述中，我们讨论了 MAO-B 抑制剂对 PD 患者运动和非运动症状的影响、其作用机制以及 MAO-B 抑制剂治疗的未来发展。
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson’s disease (PD). MAO-B inhibitor monotherapy has been shown to be effective and safe for the treatment of early-stage PD, while MAO-B inhibitors as adjuvant drugs have been widely applied for the treatment of the advanced stages of the illness. MAO-B inhibitors can effectively improve patients’ motor and non-motor symptoms, reduce “OFF” time, and may potentially prevent/delay disease progression. In this review, we discuss the effects of MAO-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy.